New first-line therapy for dMMR/MSI-H CRC
Sign Up to like & getrecommendations! Published in 2020 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-020-00464-y
Abstract: Nature reviews | CliniCal OnCOlOgy The antiPD-1 antibody pembrolizumab was approved by the FDA for patients with previously treated advancedstage mismatch repair deficient (dMMR) or microsatellite instabilityhigh (MSIH) solid tumours in May 2017. This landmark… read more here.
Keywords: chemotherapy; dmmr msih; patients dmmr; pembrolizumab ... See more keywords
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-004001
Abstract: Background Despite unprecedented benefit from immune checkpoint inhibitors (ICIs) in patients with mismatch repair deficient (dMMR)/microsatellite instability high (MSI-H) advanced gastrointestinal cancers, a relevant proportion of patients shows primary resistance or short-term disease control. Since… read more here.
Keywords: patients dmmr; immune checkpoint; peritoneal metastases; metastatic colorectal ... See more keywords